Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Pazopanib (Primary) ; Tivantinib (Primary)
- Indications Gastric cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2021 The study has amended so that the pharmacodynamic consequences of single agent pazopanib treatment could be explored through quantitation of total and phosphorylated cMET in paired tumor biopsies, longitudinal analyses of plasma levels of circulating HGF, cMET, VEGFR2, and VEGF were examined during Pazopanib and tivantinib combination treatment.
- 28 Jun 2021 Results published in the Investigational New Drugs
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology